189 related articles for article (PubMed ID: 29788419)
21. Letter: Vedolizumab in Pregnancy.
Sheridan J; Cullen G; Doherty G
J Crohns Colitis; 2017 Aug; 11(8):1025-1026. PubMed ID: 27993997
[No Abstract] [Full Text] [Related]
22. Oral Sweet's syndrome occurring in ulcerative colitis.
Nestor LA; Tobin AM
BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28298380
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis.
Westerveld D; Grajo J; Beattie L; Glover S
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28501828
[No Abstract] [Full Text] [Related]
24. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
Hedin C; Halfvarson J
Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
[TBL] [Abstract][Full Text] [Related]
25. A continuum of neutrophilic disease occurring in a patient with ulcerative colitis.
Salmon P; Rademaker M; Edwards L
Australas J Dermatol; 1998 May; 39(2):116-8. PubMed ID: 9611384
[TBL] [Abstract][Full Text] [Related]
26. A case of Sweet's syndrome associated with uveitis in a young male with ulcerative colitis.
Bancu LA; Ureche C; Crăciun NM; Marian D
Rom J Morphol Embryol; 2016; 57(3):1145-1147. PubMed ID: 28002536
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
[No Abstract] [Full Text] [Related]
28. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
29. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
[TBL] [Abstract][Full Text] [Related]
30. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
31. Sweet's syndrome complicating ulcerative colitis: a rare association.
Lopes Caçola R; Soares M; Cardoso C; Furtado A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791120
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
[No Abstract] [Full Text] [Related]
34. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
35. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
37. Sweet Syndrome in Pediatric Active Ulcerative Colitis.
Miranda E; Meza R; Kolbach M; Torres J; Harris PR
Am J Gastroenterol; 2021 Feb; 116(2):234. PubMed ID: 32341267
[No Abstract] [Full Text] [Related]
38. Real-world evidence for vedolizumab: Understanding the landscape.
Lawrance IC; Pulusu SSR
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
[No Abstract] [Full Text] [Related]
39. Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis.
Faria LM; Oliveira MM; Faria AA; Vasconcellos AVO; Cançado GGL
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):513-514. PubMed ID: 36827537
[No Abstract] [Full Text] [Related]
40. A Case of Vedolizumab-induced Acute Allergic Reaction in a Patient With Refractory Ulcerative Colitis.
Xie Y; Li H; Zhou L; Tian F
Inflamm Bowel Dis; 2022 Jul; 28(7):e103. PubMed ID: 35134937
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
